Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical ...

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

Summary: Researchers demonstrated that the success of anti-CTLA-4 immunotherapy against brain tumors does not depend on local ...

Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in ...